NCT07814001

Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy

RecruitingPHASE2INTERVENTIONAL

Trial Details

Start: 2026-12Est. Completion: 2028-07

Enrollment target: 55 participants

Locations

Hopital Henri Mondor, Créteil, France
Chu Dijon Bourgogne, Dijon, France
Chu de Lille - Hopital Claude Huriez, Lille, France
CHU de Limoges - Hopital Dupuytren, Limoges, France
Centre Léon Berard, Lyon, France
Institut Paoli Calmettes, Marseille, France
CHU de Montpellier, Montpellier, France
CHU de Nantes, Nantes, France
Hopital Necker, Paris, France
CHU de Bordeaux - Hopital Haut-Leveque, Pessac, France
CHU Lyon Sud, Pierre-Bénite, France
CHU de Poitiers - Hopital de la Miletrie, Poitiers, France
CHU Pontchaillou, Rennes, France
IUCT Oncopole, Toulouse, France
CHRU Nancy - Hopital Brabois, Vandœuvre-lès-Nancy, France

Contact

Other microbiome trials you might be interested in

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaPhase 2Recruiting

High Grade B-Cell Lymphoma With MYC and BCL6 RearrangementsRecurrent Diffuse Large B-Cell LymphomaRecurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell TypeRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRecurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 RearrangementsRecurrent High Grade B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent T-Cell/Histiocyte-Rich Large B-Cell LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell TypeRefractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.